TABLE 1.
Subject information
| Subject identifier | HLA typea | Fiebig stageb | Peak VLc | Viremia set pointd (VL) | Change in VL | CD4 count at set point |
|---|---|---|---|---|---|---|
| 01 | A*03,31 B*14,38 C*08,12 | 3–4 | 5.87 | 3.74 | −2.13 | 714 |
| 02 | A*01,32 B*08,64 C*07,08 | 3–4 | 5.53 | 4.61 | −0.92 | 517 |
| 03 | A*02,29 B*62,51 C*04,15 | 5 | 7.43 | 4.10 | −3.33 | 649 |
| 04 | A*01,02 B*08,18 C*07 | 3–4 | 5.87 | 6.10 | +0.23 | 441 |
| 05 | A*01,03 B*07,08 C*07 | 3–4 | 5.87 | 3.46 | −2.41 | 435 |
| 06 | A*01,68 B*08,40 C*02,07 | 2 | 8.04 | 6.25 | −1.79 | 280 |
| 07 | A*03,24 B*07,35 C*04,07 | 6 | NA | 5.58 | NA | 566 |
a
Intermediate-resolution typing of HLA class I A, B, and C loci, determined by reverse SSO hybridization.
b
Determined according to the method of Fiebig et al. (25) at the time of enrollment and at the first study visit.
c
VL, viral load (expressed as log copies of virus per milliliter of plasma); NA, not applicable.
d
Defined as the first point at which a subject reached a stable level of viremia in the absence of therapy (refer to Fig. 1).